Previous 10 | Next 10 |
Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Last 2 nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of Part B Total of 154 patients out of up to 183 patients (84%) now participating in...
Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“ Immutep ” or the “ Company ”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti...
Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody mole...
Immutep (NASDAQ:IMMP) announces that the first patient has been dosed in the investigator-initiated trial for the triple combination including eftilagimod alpha for the treatment of metastatic non-small cell lung carcinoma. The patient with metastatic non-small cell lung c...
Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“ Immutep ” or the “ Company ”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re in the final stretch of the week with just one more day of trading to go. So let’s start it off right with a look at the biggest pre-market stock movers for Friday! Source: Er...
Sydney, July 06, 2021 (GLOBE NEWSWIRE) -- ASX/Media Release Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval received in the United States to commence TACTI-003 Patient recruitment into the trial is expected to begin w...
Immutep (IMMP) has received commitments for a A$60M two-tranche private placement of new ordinary shares.The Placement will involve the issue of New Shares at an issue price of A$0.52/share. The proceeds will be used to fund the expansion of clinical programs and to commence the process chara...
Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of ...
Immutep (IMMP) -14% after expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapyAshford Hospitality Trust (AHT) -10% after inks stock purchase agreement with Seven Knots.BIT Mining (BTCM) -9%.Riot Blockchain (RIOT) -8%....
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...